Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Nishikawa

Showing results (21-30 of 197) with videos related to

Pageof 20
Sort By:
Nature Reviews. Clinical Oncology|February 29, 2024
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicineShogo Kumagai, Kota Itahashi, Hiroyoshi Nishikawa
European Journal of Immunology|July 25, 2022
Regulatory T-cell development in the tumor microenvironmentKota Itahashi, Takuma Irie, Hiroyoshi Nishikawa
International Immunology|March 29, 2025
Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolutionYusaku Momoi, Shogo Kumagai, Hiroyoshi Nishikawa
Nature Reviews. Clinical Oncology|February 2, 2019
Regulatory T cells in cancer immunosuppression - implications for anticancer therapyYosuke Togashi, Kohei Shitara, Hiroyoshi Nishikawa
Experimental Dermatology|December 2, 2022
Significance of regulatory T cells in cancer immunology and immunotherapyDaisuke Sugiyama, Kunihiko Hinohara, Hiroyoshi Nishikawa
Nature|January 8, 2025
Reinventing type 2 immunity in cancerMarek Wagner, Hiroyoshi Nishikawa, Shigeo Koyasu
Science Immunology|March 28, 2025
Immunogenomic cancer evolution: A framework to understand cancer immunosuppressionShogo Kumagai, Yusaku Momoi, Hiroyoshi Nishikawa
Immunotherapy|May 4, 2013
Antibody-based therapy in colorectal cancerTakuro Noguchi, Gerd Ritter, Hiroyoshi Nishikawa
Nature Reviews. Cancer|January 19, 2021
Antitumour immunity regulated by aberrant ERBB family signallingShogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa
International Immunology|October 14, 2023
Metabolic advantages of regulatory T cells dictated by cancer cellsMasaki Kondo, Shogo Kumagai, Hiroyoshi Nishikawa
Pageof 20

Showing results (21-30 of 197) with videos related to

Sort By:
Pageof 20
Nature Reviews. Clinical Oncology|February 29, 2024
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicineShogo Kumagai, Kota Itahashi, Hiroyoshi Nishikawa
European Journal of Immunology|July 25, 2022
Regulatory T-cell development in the tumor microenvironmentKota Itahashi, Takuma Irie, Hiroyoshi Nishikawa
International Immunology|March 29, 2025
Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolutionYusaku Momoi, Shogo Kumagai, Hiroyoshi Nishikawa
Nature Reviews. Clinical Oncology|February 2, 2019
Regulatory T cells in cancer immunosuppression - implications for anticancer therapyYosuke Togashi, Kohei Shitara, Hiroyoshi Nishikawa
Experimental Dermatology|December 2, 2022
Significance of regulatory T cells in cancer immunology and immunotherapyDaisuke Sugiyama, Kunihiko Hinohara, Hiroyoshi Nishikawa
Nature|January 8, 2025
Reinventing type 2 immunity in cancerMarek Wagner, Hiroyoshi Nishikawa, Shigeo Koyasu
Science Immunology|March 28, 2025
Immunogenomic cancer evolution: A framework to understand cancer immunosuppressionShogo Kumagai, Yusaku Momoi, Hiroyoshi Nishikawa
Immunotherapy|May 4, 2013
Antibody-based therapy in colorectal cancerTakuro Noguchi, Gerd Ritter, Hiroyoshi Nishikawa
Nature Reviews. Cancer|January 19, 2021
Antitumour immunity regulated by aberrant ERBB family signallingShogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa
International Immunology|October 14, 2023
Metabolic advantages of regulatory T cells dictated by cancer cellsMasaki Kondo, Shogo Kumagai, Hiroyoshi Nishikawa
Pageof 20